5. Inventories

The components of inventories are as follows (in thousands):


	December 31,
	2011		2010
Raw materials	$	10	$	7
Work-in-process(1)		591		581
Finished goods		53		198

Total	$	654	$	786

(1)	Included in work-in-process at December 31, 2011 and 2010 is $0.2 million and $0.2 million, respectively, of product awaiting final packaging.

The above inventory balances relate to the manufacturing of Qutenza and are costs capitalized since the Company received FDA approval for the sale of Qutenza in the US market in the fourth quarter of 2009. Prior to FDA approval, all manufacturing and product related costs for Qutenza and for the Company's other development programs were expensed to research and development. On a quarterly basis, the Company analyzes its inventory levels and writes down inventory that has become obsolete, inventory that has a cost basis in excess of the expected net realizable value and inventory that is in excess of expected requirements based upon anticipated product revenues. In each of the years ended December 31, 2011 and 2010, the Company recorded a charge to Cost of goods sold of $0.4 million for Qutenza patches which the Company does not expect to sell prior to their expiration date.